GPA33 Expression in Colorectal Cancer and Its Potential for Targeted Therapy
Author Information
Author(s): Börding Teresa, Janik Tobias, Bischoff Philip, Morkel Markus, Sers Christine, Horst David
Primary Institution: Charité – Universitätsmedizin Berlin
Hypothesis
Can GPA33 expression in colorectal cancer be induced by WNT inhibition and targeted by cellular therapy?
Conclusion
GPA33 is a promising target for cellular immunotherapy in colorectal cancer, and its expression can be enhanced by WNT inhibition.
Supporting Evidence
- GPA33 is expressed almost exclusively in colorectal cancer and intestinal epithelia.
- Low GPA33 expression levels were linked to tumor progression in patients with CRC.
- GPA33-CAR T cells were activated in response to GPA33 and reduced xenograft growth in mice.
- GPA33 expression showed consistent intratumoral heterogeneity in CRC.
- Downregulation of WNT activity induced GPA33 expression in vitro and in GPA33-negative tumor cell subpopulations.
Takeaway
GPA33 is a special marker found in most colorectal cancers, and scientists found a way to make more of it appear in cancer cells, which could help in treating the disease.
Methodology
The study involved immunohistochemistry and immunofluorescence to analyze GPA33 expression, and in vitro and in vivo experiments to assess the effects of WNT inhibitors and CAR T cell therapy.
Potential Biases
Potential bias in patient selection and tumor heterogeneity may affect the results.
Limitations
The study may not fully account for all resistance mechanisms against GPA33-targeted therapy.
Participant Demographics
The study analyzed 223 primary UICC stage II colorectal cancer cases and 438 patients from the TCGA-COAD cohort.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website